• Safety
  • Safety Profile

TRODELVY 200mg

Safety

TRODELVY has a well-characterised safety profile1

Adverse events of special interest in the ASCENT trial2

Response

In ASCENT, approximately 80% of patients stayed on the full TRODELVY dose without the need for a dose reduction§2

There are minor differences in the adverse event rates shown above compared with those reported in the Summary of Product Characteristics, which uses pooled data from 2 clinical trials (ASCENT and IMMU-132-01).

*The neutropenia category included neutropenia and decreased neutrophil count.
†The anaemia category included anaemia, decreased hemoglobin level, and decreased red cell count.
‡The leukopenia category included leukopenia and decreased white cell count.
§Dose reductions due to AEs occurred with similar frequency in the two groups
(22% of the patients who received TRODELVY and 26% of those who received chemotherapy).

ABBREVIATIONS:

AE, adverse event.

REFERENCES:

  1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics. February 2023.
  2. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.